

Rebecca C Fitzgerald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4040048/publications.pdf>

Version: 2024-02-01

212
papers

15,782
citations

17440

63
h-index

20961

115
g-index

225
all docs

225
docs citations

225
times ranked

15346
citing authors

#	ARTICLE	IF	CITATIONS
1	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2014, 63, 7-42.	12.1	1,116
2	Somatic mutant clones colonize the human esophagus with age. <i>Science</i> , 2018, 362, 911-917.	12.6	805
3	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	30.5	671
4	scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation. <i>Genome Biology</i> , 2020, 21, 1.	8.8	572
5	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. <i>Journal of Medical Genetics</i> , 2015, 52, 361-374.	3.2	479
6	The landscape of somatic mutation in normal colorectal epithelial cells. <i>Nature</i> , 2019, 574, 532-537.	27.8	468
7	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. <i>Nature Genetics</i> , 2016, 48, 1131-1141.	21.4	332
8	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. <i>Nature Genetics</i> , 2014, 46, 837-843.	21.4	302
9	Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. <i>Journal of Clinical Investigation</i> , 1996, 98, 2120-2128.	8.2	298
10	Early detection of cancer. <i>Science</i> , 2022, 375, eaay9040.	12.6	291
11	Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. <i>Nature Medicine</i> , 2012, 18, 315-321.	30.7	285
12	Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. <i>Nature Genetics</i> , 2020, 52, 306-319.	21.4	275
13	Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4372-c4372.	2.3	271
14	Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. <i>Nature Genetics</i> , 2015, 47, 1038-1046.	21.4	262
15	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , The, 2020, 21, e386-e397.	10.7	237
16	Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. <i>Gut</i> , 2002, 50, 451-459.	12.1	229
17	Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case-Control Study. <i>PLoS Medicine</i> , 2015, 12, e1001780.	8.4	212
18	Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. <i>Nature Communications</i> , 2018, 9, 2983.	12.8	206

#	ARTICLE	IF	CITATIONS
19	Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. <i>Lancet, The</i> , 2018, 392, 400-408.	13.7	199
20	Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy. <i>Gastroenterology</i> , 2018, 154, 421-436.	1.3	182
21	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. <i>Gastroenterology</i> , 2010, 138, 854-869.	1.3	181
22	The mutational landscape of human somatic and germline cells. <i>Nature</i> , 2021, 597, 381-386.	27.8	180
23	A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. <i>Nature Genetics</i> , 2013, 45, 1487-1493.	21.4	174
24	The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. <i>Nature Genetics</i> , 2019, 51, 506-516.	21.4	166
25	Population-Based Study Reveals New Risk-Stratification Biomarker Panel for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 927-935.e3.	1.3	151
26	International cancer seminars: a focus on esophageal squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2086-2093.	1.2	149
27	Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett's Esophagus. <i>Gastroenterology</i> , 2013, 144, 62-73.e6.	1.3	146
28	Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2177-2182.	7.1	143
29	Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 333-344.	13.7	143
30	A Deep Learning Framework for Predicting Response to Therapy in Cancer. <i>Cell Reports</i> , 2019, 29, 3367-3373.e4.	6.4	137
31	A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia. <i>Gastroenterology</i> , 2010, 139, 1995-2004.e15.	1.3	135
32	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology, The</i> , 2016, 17, 1363-1373.	10.7	133
33	Accuracy, Safety, and Tolerability of Tissue Collection by Cytosponge vs Endoscopy for Evaluation of Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 77-83.e2.	4.4	132
34	Precision prevention of oesophageal adenocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 243-248.	17.8	129
35	Screening for oesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 278-287.	27.6	124
36	Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. <i>Journal of Pathology</i> , 2008, 216, 295-306.	4.5	122

#	ARTICLE	IF	CITATIONS
37	Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2006, 55, 1810-1820.	12.1	118
38	A non-endoscopic device to sample the oesophageal microbiota: a case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 32-42.	8.1	111
39	Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. <i>Journal of Pathology</i> , 2008, 216, 286-294.	4.5	108
40	Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1892-1898.	2.3	106
41	Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 954-961.	1.0	105
42	Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. <i>Gut</i> , 2009, 58, 1451-1459.	12.1	104
43	A review of the current understanding and clinical utility of miRNAs in esophageal cancer. <i>Seminars in Cancer Biology</i> , 2013, 23, 512-521.	9.6	104
44	High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. <i>Gastroenterology</i> , 2019, 157, 492-506.e2.	1.3	100
45	Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition. <i>Science</i> , 2021, 373, 760-767.	12.6	99
46	Barrett oesophagus. <i>Nature Reviews Disease Primers</i> , 2019, 5, 35.	30.5	98
47	Nitric Oxide and Acid Induce Double-Strand DNA Breaks in Barrett's Esophagus Carcinogenesis via Distinct Mechanisms. <i>Gastroenterology</i> , 2007, 133, 1198-1209.	1.3	94
48	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, 367-378.	1.3	93
49	The future of early cancer detection. <i>Nature Medicine</i> , 2022, 28, 666-677.	30.7	92
50	Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1816-1828.	0.3	88
51	Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 23-31.	8.1	87
52	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 489-498.	8.1	87
53	Extensive phylogenies of human development inferred from somatic mutations. <i>Nature</i> , 2021, 597, 387-392.	27.8	87
54	Genomic copy number predicts esophageal cancer years before transformation. <i>Nature Medicine</i> , 2020, 26, 1726-1732.	30.7	86

#	ARTICLE	IF	CITATIONS
55	Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 408-418.	1.0	85
56	Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. <i>Gut</i> , 2004, 53, 775-778.	12.1	84
57	Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. <i>Gut</i> , 2018, 67, 392-393.	12.1	80
58	Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. <i>Nature Genetics</i> , 2020, 52, 1178-1188.	21.4	79
59	Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1538-1544.	0.4	76
60	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
61	Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 78-87.	1.0	75
62	Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. <i>Gut</i> , 2018, 67, 1942-1949.	12.1	75
63	A clinically translatable hyperspectral endoscopy (HySE) system for imaging the gastrointestinal tract. <i>Nature Communications</i> , 2019, 10, 1902.	12.8	75
64	Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. <i>Clinical Cancer Research</i> , 2003, 9, 2560-6.	7.0	74
65	Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. <i>Nature Genetics</i> , 2021, 53, 1553-1563.	21.4	71
66	The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , 2017, 153, 657-673.e1.	1.3	69
67	Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. <i>Gastroenterology</i> , 2018, 154, 1273-1281.e3.	1.3	67
68	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	1.3	67
69	Three-Gene Immunohistochemical Panel Adds to Clinical Staging Algorithms to Predict Prognosis for Patients With Esophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1576-1582.	1.6	66
70	Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance. <i>Clinical Cancer Research</i> , 2007, 13, 659-665.	7.0	65
71	DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus. <i>Clinical Cancer Research</i> , 2013, 19, 878-888.	7.0	65
72	Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning. <i>Nature Medicine</i> , 2021, 27, 833-841.	30.7	65

#	ARTICLE	IF	CITATIONS
73	Evidence for a functional role of epigenetically regulated midcluster <i>HOXB</i> genes in the development of Barrett esophagus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9077-9082.	7.1	62
74	The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. <i>Gut</i> , 2015, 64, 49-56.	12.1	60
75	Acid modulation of HT29 cell growth and differentiation An in vitro model for Barrett's esophagus. <i>Journal of Cell Science</i> , 1997, 110, 663-671.	2.0	60
76	Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. <i>Gut</i> , 2005, 54, i21-i26.	12.1	59
77	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. <i>Nature Communications</i> , 2019, 10, 4219.	12.8	58
78	Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. <i>Gastroenterology</i> , 2020, 158, 1682-1697.e1.	1.3	58
79	Screening for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, 912-923.	1.3	54
80	Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 647-656.e1.	4.4	54
81	Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 74-83.	21.4	53
82	Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. <i>Annals of Oncology</i> , 2021, 32, 522-532.	1.2	53
83	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	6.4	51
84	Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2016, 115, 403-410.	6.4	49
85	Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G47-G55.	3.4	47
86	Barrett's oesophagus, dysplasia and pharmacologic acid suppression. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 269-276.	3.7	47
87	Identification and Clinical Implementation of Biomarkers for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 142, 435-441.e2.	1.3	45
88	Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. <i>Histopathology</i> , 2017, 70, 203-210.	2.9	45
89	The Impact of Prophylactic Total Gastrectomy on Health-Related Quality of Life. <i>Annals of Surgery</i> , 2014, 260, 87-93.	4.2	44
90	Chromosomal copy number heterogeneity predicts survival rates across cancers. <i>Nature Communications</i> , 2021, 12, 3188.	12.8	43

#	ARTICLE	IF	CITATIONS
91	Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. <i>PLoS Genetics</i> , 2017, 13, e1006879.	3.5	41
92	New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?. <i>Gastroenterology</i> , 2018, 154, 1594-1601.	1.3	39
93	Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	38
94	Body Mass Index, Smoking, and Alcohol and Risks of Barrett's Esophagus and Esophageal Adenocarcinoma: A UK Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1552-1559.	2.3	38
95	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017, 66, 1739-1747.	12.1	38
96	Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus. <i>Gastroenterology</i> , 2018, 155, 771-783.e3.	1.3	38
97	Barrett's oEsophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux. <i>BMC Cancer</i> , 2018, 18, 784.	2.6	37
98	Developing a nonendoscopic screening test for Barrett's esophagus. <i>Biomarkers in Medicine</i> , 2011, 5, 397-404.	1.4	35
99	Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. <i>Journal of Pathology</i> , 2013, 230, 118-128.	4.5	35
100	Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. <i>British Journal of Cancer</i> , 2014, 111, 2235-2241.	6.4	35
101	Machine learning to predict early recurrence after oesophageal cancer surgery. <i>British Journal of Surgery</i> , 2020, 107, 1042-1052.	0.3	35
102	Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett's esophagus. <i>Endoscopy</i> , 2016, 48, 110-116.	1.8	34
103	Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 3101.	12.8	34
104	Evolution and progression of Barrett's oesophagus to oesophageal cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 731-741.	28.4	32
105	Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2014, 35, 2740-2747.	2.8	31
106	Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 638-646.e1.	4.4	30
107	The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). <i>Journal of Genetic Counseling</i> , 2017, 26, 752-762.	1.6	29
108	An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). <i>Familial Cancer</i> , 2016, 15, 665-676.	1.9	28

#	ARTICLE	IF	CITATIONS
109	Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot. <i>Lancet Oncology</i> , The, 2022, 23, 270-278.	10.7	28
110	A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. <i>Genome Research</i> , 2017, 27, 902-912.	5.5	27
111	Gastro-Esophageal Reflux Disease Symptoms and Demographic Factors as a Pre-Screening Tool for Barrett's Esophagus. <i>PLoS ONE</i> , 2014, 9, e94163.	2.5	27
112	A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	26
113	Analysis of Dysplasia in Patients With Barrett's Esophagus Based on Expression Pattern of 90 Genes. <i>Gastroenterology</i> , 2015, 149, 1511-1518.e5.	1.3	25
114	Review article: Barrett's oesophagus and associated adenocarcinoma - a UK perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 45-49.	3.7	24
115	Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2015, 110, 1549-1558.	0.4	24
116	The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 558-566.	1.5	24
117	Design and validation of a near-infrared fluorescence endoscope for detection of early esophageal malignancy. <i>Journal of Biomedical Optics</i> , 2016, 21, 084001.	2.6	23
118	Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. <i>F1000Research</i> , 2016, 5, 1336.	1.6	23
119	Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device—The Cytosponge TM . <i>Diagnostic Cytopathology</i> , 2020, 48, 253-264.	1.0	22
120	MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. <i>PLoS ONE</i> , 2015, 10, e0128617.	2.5	21
121	Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis. <i>BMC Genomics</i> , 2015, 16, 473.	2.8	21
122	Detection of early neoplasia in Barrett's esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue. <i>Endoscopy</i> , 2018, 50, 618-625.	1.8	21
123	Non-endoscopic immunocytological screening test for Barrett's oesophagus. <i>Gut</i> , 2007, 56, 1033-1034.	12.1	20
124	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. <i>Scientific Reports</i> , 2016, 6, 32417.	3.3	20
125	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 1454.	12.8	20
126	Big data is crucial to the early detection of cancer. <i>Nature Medicine</i> , 2020, 26, 19-20.	30.7	19

#	ARTICLE	IF	CITATIONS
127	Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach. <i>The Lancet Digital Health</i> , 2020, 2, e37-e48.	12.3	19
128	Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study. <i>EBioMedicine</i> , 2020, 56, 102765.	6.1	19
129	Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis. <i>PLoS Genetics</i> , 2017, 13, e1006808.	3.5	19
130	Biomarkers in Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 373-390.	2.2	18
131	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.	12.1	18
132	Past, present and future of Barrett's oesophagus. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1148-1160.	1.0	17
133	Early detection and therapeutics. <i>Molecular Oncology</i> , 2019, 13, 599-613.	4.6	17
134	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. <i>International Journal of Cancer</i> , 2019, 145, 3389-3401.	5.1	17
135	Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1709-1718.	4.4	17
136	Screening and Risk Stratification for Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2013, 42, 155-173.	2.2	16
137	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1598-1606.e4.	4.4	16
138	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2227-2235.e1.	4.4	16
139	Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , 2020, 159, 2065-2076.e1.	1.3	16
140	Hereditary Diffuse Gastric Cancer: Approaches to Screening, Surveillance, and Treatment. <i>Annual Review of Medicine</i> , 2021, 72, 263-280.	12.2	15
141	Multi-omic cross-sectional cohort study of pre-malignant Barrett's esophagus reveals early structural variation and retrotransposon activity. <i>Nature Communications</i> , 2022, 13, 1407.	12.8	15
142	Progressive silencing of p14ARF in oesophageal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 398-409.	3.6	14
143	Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 805-806.	8.1	13
144	Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. <i>International Journal of Cancer</i> , 2021, 148, 1208-1218.	5.1	13

#	ARTICLE	IF	CITATIONS
145	Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. <i>Gut</i> , 0, , gutjnl-2022-327281.	12.1	13
146	Evolutionary dynamics in pre-invasive neoplasia. <i>Current Opinion in Systems Biology</i> , 2017, 2, 1-8.	2.6	12
147	Alternatives to Traditional Per-Oral Endoscopy for Screening. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017, 27, 379-396.	1.4	12
148	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2701-2709.e3.	4.4	12
149	Post-endoscopy Esophageal Neoplasia in Barrett's Esophagus: Consensus Statements From an International Expert Panel. <i>Gastroenterology</i> , 2022, 162, 366-372.	1.3	12
150	Genomic instability signals offer diagnostic possibility in early cancer detection. <i>Trends in Genetics</i> , 2021, 37, 966-972.	6.7	11
151	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. <i>ACS Chemical Biology</i> , 2022, 17, 1876-1889.	3.4	11
152	1004 Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). <i>Gastroenterology</i> , 2013, 144, S-187.	1.3	10
153	Targeting care in Barrett's oesophagus. <i>Clinical Medicine</i> , 2014, 14, s78-s83.	1.9	10
154	Biomarkers for Dysplastic Barrett's: Ready for Prime Time?. <i>World Journal of Surgery</i> , 2015, 39, 568-577.	1.6	10
155	Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2016, 138, 1146-1152.	5.1	10
156	Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. <i>PLoS ONE</i> , 2015, 10, e0138738.	2.5	9
157	The mutREAD method detects mutational signatures from low quantities of cancer DNA. <i>Nature Communications</i> , 2020, 11, 3166.	12.8	9
158	Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 3394.	3.7	9
159	The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 263-270.e2.	1.0	9
160	Testosterone concentrations in men on chronic glucocorticosteroid therapy. <i>Journal of the Royal College of Physicians of London</i> , 1997, 31, 168-70.	0.2	9
161	Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 258-267.	3.0	8
162	Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2105-2114.	2.3	8

#	ARTICLE	IF	CITATIONS
163	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. <i>Gastroenterology</i> , 2021, 161, 1705-1708.e2.	1.3	8
164	Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas. <i>Communications Biology</i> , 2022, 5, 335.	4.4	8
165	High-risk individuals' perceptions of reproductive genetic testing for CDH1 mutations. <i>Familial Cancer</i> , 2017, 16, 531-535.	1.9	7
166	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 427-433.	2.5	7
167	Progress in Screening for Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 43-58.	1.4	7
168	Evidence that polyploidy in esophageal adenocarcinoma originates from mitotic slippage caused by defective chromosome attachments. <i>Cell Death and Differentiation</i> , 2021, 28, 2179-2193.	11.2	7
169	958 Time: A Prospective Study Combining Endoscopic Trimodal Imaging and Molecular Endpoints to Improve Risk Stratification in Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 142, S-165.	1.3	6
170	54 Evaluation of a Minimally-Invasive Cytosponge Esophageal Cell Collection System in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, S-16.	1.3	6
171	Combining simple patient-oriented tests with state-of-the-art molecular diagnostics for early diagnosis of cancer. <i>United European Gastroenterology Journal</i> , 2015, 3, 226-229.	3.8	6
172	Genomics of Esophageal Cancer and Biomarkers for Early Detection. <i>Advances in Experimental Medicine and Biology</i> , 2016, 908, 237-263.	1.6	6
173	Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial. <i>BMJ Open</i> , 2022, 12, e054258.	1.9	6
174	Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
175	Women in hospital medicine: career choices and opportunities. <i>British Journal of Hospital Medicine</i> , 2001, 62, 778-779.	0.2	5
176	Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1099-1104.	6.4	5
177	Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2710-2716.e1.	4.4	5
178	Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. <i>Endoscopy</i> , 2021, 53, 246-253.	1.8	5
179	Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. <i>Cancer Prevention Research</i> , 2021, 14, 675-682.	1.5	5
180	Screening for Barrett's Oesophagus: Are We Ready for it?. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 321-336.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. <i>EClinicalMedicine</i> , 2021, 37, 100969.	7.1	5
182	The utility of <scp>P53</scp> immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia. <i>Histopathology</i> , 2022, 80, 1081-1090.	2.9	5
183	Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 21-21.	3.0	4
184	A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	4
185	Time to Challenge Current Strategies for Detection of Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 2020, 65, 18-21.	2.3	4
186	Signatures of Mutational Processes and Associated Risk Factors in Esophageal Squamous Cell Carcinoma: A Geographically Independent Stratification Strategy?. <i>Gastroenterology</i> , 2016, 150, 1080-1083.	1.3	3
187	Organ-preserving approaches in oesophageal cancer. <i>Lancet Oncology</i> , The, 2018, 19, 858-859.	10.7	3
188	Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus?. <i>Gastroenterology</i> , 2019, 156, 1228-1231.	1.3	3
189	Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. <i>Journal of Clinical Pathology</i> , 2019, 72, 825-829.	2.0	3
190	Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study. <i>Cancer Medicine</i> , 2022, 11, 1160-1171.	2.8	3
191	Early Diagnosis of Gastroesophageal Cancers and the Cytosponge: A Work in Progress. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 4, 447.	4.5	2
192	Conference report: improving outcomes for gastrointestinal cancer in the UK. <i>Frontline Gastroenterology</i> , 2018, 9, 49-61.	1.8	2
193	Barrett's oesophagus and oesophageal adenocarcinoma. <i>Medicine</i> , 2019, 47, 275-285.	0.4	2
194	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e51-e63.	4.4	2
195	Cytosponge-TFF3 Testing can Detect Precancerous Mucosal Changes of the Stomach. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1411-1412.	4.4	2
196	Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning. <i>EBioMedicine</i> , 2022, 82, 104160.	6.1	2
197	Leadership roles for women in gastroenterology: New initiatives for the new generation of gastroenterologists. <i>United European Gastroenterology Journal</i> , 2016, 4, 815-815.	3.8	1
198	A multicentre cohort study to redefine and validate pathological assessment of response to neoadjuvant therapy in treated oesophagogastric adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2016, 42, S252.	1.0	1

#	ARTICLE	IF	CITATIONS
199	The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus. <i>EBioMedicine</i> , 2020, 58, 102877.	6.1	1
200	Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2257-2261.	1.0	1
201	Practical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues. <i>British Journal of Cancer</i> , 2021, 124, 683-685.	6.4	1
202	Screening for Barrett Esophagus With a Nonendoscopic Sponge Capsule. <i>Gastroenterology and Hepatology</i> , 2015, 11, 623-5.	0.1	1
203	Alterations in the Ca ²⁺ toolkit in oesophageal adenocarcinoma. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, .	0.8	1
204	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	2.5	1
205	Medicine is the ultimate personalised technology. <i>BMJ: British Medical Journal</i> , 2017, 357, j1750.	2.3	0
206	DNA Methylation Biomarkers for the Diagnosis of Barrett's Oesophagus. <i>American Journal of Gastroenterology</i> , 2018, 113, 1722.	0.4	0
207	Surveillance and Endoscopic Recognition of Gastric Intestinal Metaplasia and Atrophic Gastritis: A Retrospective Cohort Study in Two Academic Centers. , 2021, 53, .		0
208	National clinician scientist posts. <i>BMJ: British Medical Journal</i> , 2002, 325, 101S-101.	2.3	0
209	Abstract 1189: Chromosomal aberrations reveal novel genes with prognostic significance in esophageal adenocarcinoma. , 2010, , .		0
210	Genetics and Biomarkers in Barrett's Esophagus and Esophageal Adenocarcinoma. , 2016, , 37-60.		0
211	OFR-5...Surveillance and endoscopic recognition of gastric intestinal metaplasia and atrophic gastritis. , 2021, , .		0
212	Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples. <i>EBioMedicine</i> , 2022, 76, 103814.	6.1	0